Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Haleema Azam, Shane Maher, Shane Clarke, William M. Gallagher & Maria Prencipe. (2023) SRF inhibitors reduce prostate cancer cell proliferation through cell cycle arrest in an isogenic model of castrate-resistant prostate cancer. Cell Cycle 22:14-16, pages 1759-1776.
Read now
Read now
Haleema Azam, Lisa Pierro, Martina Reina, William M Gallagher & Maria Prencipe. (2022) Emerging role for the Serum Response Factor (SRF) as a potential therapeutic target in cancer. Expert Opinion on Therapeutic Targets 26:2, pages 155-169.
Read now
Read now
Justin J. Bailey, Ralf Schirrmacher, Kristen Farrell & Vadim Bernard-Gauthier. (2017) Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part II. Expert Opinion on Therapeutic Patents 27:7, pages 831-849.
Read now
Read now
Justin J. Bailey, Ralf Schirrmacher, Kristen Farrell & Vadim Bernard-Gauthier. (2017) Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part I. Expert Opinion on Therapeutic Patents 27:6, pages 733-751.
Read now
Read now
Mohammad Hojjat-Farsangi. (2016) Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances. Journal of Drug Targeting 24:3, pages 192-211.
Read now
Read now
Zhijie Li, Yi Zhang, Yuxin Tong, Jenna Tong & Carol J Thiele. (2015) Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo. Cancer Biology & Therapy 16:3, pages 477-483.
Read now
Read now
Clive McCarthy & Edward Walker. (2014) Tropomyosin receptor kinase inhibitors: a patent update 2009 – 2013. Expert Opinion on Therapeutic Patents 24:7, pages 731-744.
Read now
Read now
Raoul Tibes, James M Bogenberger, Holly L Geyer & Ruben A Mesa. (2012) JAK2 inhibitors in the treatment of myeloproliferative neoplasms. Expert Opinion on Investigational Drugs 21:12, pages 1755-1774.
Read now
Read now
Articles from other publishers (52)
Gianmarco Pallavicini, Giorgia Iegiani, Roberta Parolisi, Alessia Ferraro, Francesca Garello, Valeria Bitonto, Enzo Terreno, Marta Gai & Ferdinando Di Cunto. (2023) Lestaurtinib inhibits Citron kinase activity and medulloblastoma growth through induction of DNA damage, apoptosis and cytokinesis failure. Frontiers in Oncology 13.
Crossref
Crossref
Yi-Xiang Zhang, Min-Yi Ou, Zi-Han Yang, Yu Sun, Qing-Feng Li & Shuang-Bai Zhou. (2023) Adipose tissue aging is regulated by an altered immune system. Frontiers in Immunology 14.
Crossref
Crossref
Lucia Cappabianca, Veronica Zelli, Cristina Pellegrini, Michela Sebastiano, Rita Maccarone, Marco Clementi, Alessandro Chiominto, Pierdomenico Ruggeri, Ludovica Cardelli, Marianna Ruggieri, Maddalena Sbaffone, Maria-Concetta Fargnoli, Stefano Guadagni, Antonietta R. Farina & Andrew R. Mackay. (2023) The Alternative TrkAIII Splice Variant, a Targetable Oncogenic Participant in Human Cutaneous Malignant Melanoma. Cells 12:2, pages 237.
Crossref
Crossref
Fahim Anwar Rizwi, Md. Abubakar, Eswara Rao Puppala, Ahsas Goyal, Ch. Veera Bhadrawamy, V. G. M. Naidu, S. Roshan, B. Tazneem, Waleed Hassan Almalki, Vetriselvan Subramaniyan, Sushama Rawat & Gaurav Gupta. (2023) Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of Cancer. Journal of Environmental Pathology, Toxicology and Oncology 42:4, pages 15-29.
Crossref
Crossref
Zhe Li, Wei Mu & Min Xiao. (2023) Genetic lesions and targeted therapy in Hodgkin lymphoma. Therapeutic Advances in Hematology 14, pages 204062072211492.
Crossref
Crossref
Amit Kumar, Luni Emdad, Paul B. Fisher & Swadesh K. Das. 2023. Epigenetic Regulation of Cancer in Response to Chemotherapy. Epigenetic Regulation of Cancer in Response to Chemotherapy
73
161
.
Manali Singha, Limeng Pu, Brent A. Stanfield, Ifeanyi K. Uche, Paul J. F. Rider, Konstantin G. Kousoulas, J. Ramanujam & Michal Brylinski. (2022) Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors. BMC Cancer 22:1.
Crossref
Crossref
Sibasish Mohanty, Pallavi Mohapatra, Omprakash Shriwas, Shamima Azma Ansari, Manashi Priyadarshini, Swatismita Priyadarsini, Rachna Rath, Mahesh Sultania, Saroj Kumar Das Majumdar, Rajeeb K. Swain & Rupesh Dash. (2022) CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis. Oncogene 41:45, pages 4929-4940.
Crossref
Crossref
Lucia Cappabianca, Michela Sebastiano, Marianna Ruggieri, Maddalena Sbaffone, Veronica Zelli, Antonietta Rosella Farina & Andrew Reay Mackay. (2022) Doxorubicin-Induced TrkAIII Activation: A Selection Mechanism for Resistant Dormant Neuroblastoma Cells. International Journal of Molecular Sciences 23:18, pages 10895.
Crossref
Crossref
Pei Shen, Yezhi Wang, Xiangxiang Jia, Pengfei Xu, Lian Qin, Xi Feng, Zhiyu Li & Zhixia Qiu. (2022) Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases. European Journal of Medicinal Chemistry 239, pages 114551.
Crossref
Crossref
Yuanchun Zhao, Jiachen Zuo, Yiming Shen, Donghui Yan, Jiajia Chen & Xin Qi. (2022) Identification of Novel Drugs Targeting Cell Cycle Regulators for the Treatment of High-Grade Serous Ovarian Cancer via Integrated Bioinformatics Analysis. Symmetry 14:7, pages 1403.
Crossref
Crossref
Qing Ye & Nancy Lan Guo. (2022) Single B Cell Gene Co-Expression Networks Implicated in Prognosis, Proliferation, and Therapeutic Responses in Non-Small Cell Lung Cancer Bulk Tumors. Cancers 14:13, pages 3123.
Crossref
Crossref
Shuang Wu, Shihai Liu, Yan Li, Changchang Liu & Huazheng Pan. (2022) Lestaurtinib Has the Potential to Inhibit the Proliferation of Hepatocellular Carcinoma Uncovered by Bioinformatics Analysis and Pharmacological Experiments. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Jennifer C. Zhao, Sonal Agarwal, Hiba Ahmad, Kejal Amin, Jan Philipp Bewersdorf & Amer M. Zeidan. (2022) A review of FLT3 inhibitors in acute myeloid leukemia. Blood Reviews 52, pages 100905.
Crossref
Crossref
Qing Ye, Brianne Falatovich, Salvi Singh, Alexey V. Ivanov, Timothy D. Eubank & Nancy Lan Guo. (2021) A Multi-Omics Network of a Seven-Gene Prognostic Signature for Non-Small Cell Lung Cancer. International Journal of Molecular Sciences 23:1, pages 219.
Crossref
Crossref
Anna Caruso, Alexia Barbarossa, Alessia Carocci, Giovanni Salzano, Maria Stefania Sinicropi & Carmela Saturnino. (2021) Carbazole Derivatives as STAT Inhibitors: An Overview. Applied Sciences 11:13, pages 6192.
Crossref
Crossref
Huan Wang, Qiming Zheng, Zeyi Lu, Liya Wang, Lifeng Ding, Liqun Xia, Hao Zhang, Mingchao Wang, Yicheng Chen & Gonghui Li. (2021) Role of the nervous system in cancers: a review. Cell Death Discovery 7:1.
Crossref
Crossref
Adrián Mosquera Orgueira, Laura Bao Pérez, Alicia Mosquera Torre, Andrés Peleteiro Raíndo, Miguel Cid López, José Á. Díaz Arias, Roi Ferreiro Ferro, Beatriz Antelo Rodríguez, Marta S. González Pérez, Manuel Albors Ferreiro, Natalia Alonso Vence, Manuel M. Pérez Encinas, José L. Bello López, Giovanni Martinelli & Claudio Cerchione. (2020) FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives. Minerva Medica 111:5.
Crossref
Crossref
Lexian Tong, Xuemei Li, Yongzhou Hu & Tao Liu. (2020) Recent advances in FLT3 inhibitors for acute myeloid leukemia. Future Medicinal Chemistry 12:10, pages 961-981.
Crossref
Crossref
Ali H. Zahalka & Paul S. Frenette. (2020) Nerves in cancer. Nature Reviews Cancer 20:3, pages 143-157.
Crossref
Crossref
Varadha Balaji Venkadakrishnan, Adam D. DePriest, Sangeeta Kumari, Dhirodatta Senapati, Salma Ben-Salem, Yixue Su, Giridhar Mudduluru, Qiang Hu, Eduardo Cortes, Elena Pop, James L. Mohler, Gissou Azabdaftari, Kristopher Attwood, Rajal B. Shah, Christina Jamieson, Scott M. Dehm, Cristina Magi-Galluzzi, Eric Klein, Nima Sharifi, Song Liu & Hannelore V. Heemers. (2019) Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. Oncogene 38:23, pages 4496-4511.
Crossref
Crossref
Xue Yuan, Yong Chen, Wanhua Zhang, Jun He, Lei Lei, Minghai Tang, Jiang Liu, Muzhou Li, Caixia Dou, Tao Yang, Linyu Yang, Shengyong Yang, Yuquan Wei, Aihua Peng, Ting Niu, Mingli Xiang, Haoyu Ye & Lijuan Chen. (2019)
Identification of Pyrrolo[2,3-
d
]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia
. Journal of Medicinal Chemistry 62:8, pages 4158-4173.
Crossref
Crossref
Mohmmad Shoab Mansuri & Sonam Mehrotra. 2019. Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach. Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach
157
188
.
Yuan Ling, Qing Xie, Zikang Zhang & Hua Zhang. (2018) Protein kinase inhibitors for acute leukemia. Biomarker Research 6:1.
Crossref
Crossref
Chong Ning, Hui-Min David Wang, Rong Gao, Yu-Chia Chang, Fengqing Hu, Xianjun Meng & Shi-Ying Huang. (2018) Marine-derived protein kinase inhibitors for neuroinflammatory diseases. BioMedical Engineering OnLine 17:1.
Crossref
Crossref
Ryosuke OkamuraAmélie BoichardShumei KatoJason K. SicklickLyudmila BazhenovaRazelle Kurzrock. (2018)
Analysis of
NTRK
Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics
. JCO Precision Oncology:2, pages 1-20.
Crossref
Crossref
Satoshi Ōmura, Yukihiro Asami & Andy Crump. (2018) Staurosporine: new lease of life for parent compound of today’s novel and highly successful anti-cancer drugs. The Journal of Antibiotics 71:8, pages 688-701.
Crossref
Crossref
Lingtao Jin, Jaemoo Chun, Chaoyun Pan, Dan Li, Ruiting Lin, Gina N. Alesi, Xu Wang, Hee-Bum Kang, Lina Song, Dongsheng Wang, Guojing Zhang, Jun Fan, Titus J. Boggon, Lu Zhou, Jeanne Kowalski, Cheng-Kui Qu, Conor E. Steuer, Georgia Z. Chen, Nabil F. Saba, Lawrence H. Boise, Taofeek K. Owonikoko, Fadlo R. Khuri, Kelly R. Magliocca, Dong M. Shin, Sagar Lonial & Sumin Kang. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell 34:2, pages 315-330.e7.
Crossref
Crossref
Jie Yang See, Hui Yang, Yu Zhao, Ming Wah Wong, Zhihai Ke & Ying-Yeung Yeung. (2018) Desymmetrizing Enantio- and Diastereoselective Selenoetherification through Supramolecular Catalysis. ACS Catalysis 8:2, pages 850-858.
Crossref
Crossref
Amy Cranston, Deborah D. Stocken, Elaine Stamp, David Roblin, Julia Hamlin, James Langtry, Ruth Plummer, Alan Ashworth, John Burn & Neil Rajan. (2017) Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial. Trials 18:1.
Crossref
Crossref
Amir Tajbakhsh, Amin Mokhtari-Zaer, Mehdi Rezaee, Fahimeh Afzaljavan, Mehdi Rivandi, Seyed Mahdi Hassanian, Gordon A Ferns, Alireza Pasdar & Amir Avan. (2017) Therapeutic Potentials of BDNF/TrkB in Breast Cancer; Current Status and Perspectives. Journal of Cellular Biochemistry 118:9, pages 2502-2515.
Crossref
Crossref
Carlos Best-Aguilera, O. Rodrigo Gómez-Vázquez, A. Elizabeth Guzmán-Hernández & R. Monserrat Rojas-Sotelo. (2017) Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation. Current Oncology Reports 19:3.
Crossref
Crossref
Matthew D Johnson, Brandon Stone, Bryan J Thibodeau, Andrew M Baschnagel, Sandra Galoforo, Laura E Fortier, Billie Ketelsen, Samreen Ahmed, Zakiya Kelley, Alaa Hana, Thomas G Wilson, John M Robertson, Robert P Jury & George D Wilson. (2017) The significance of Trk receptors in pancreatic cancer. Tumor Biology 39:2, pages 101042831769225.
Crossref
Crossref
N.F. Frydenlund & M. Mahalingam. 2017. Neurotrophins. Neurotrophins
497
531
.
Ming Xu, Tamar Tchkonia & James L. Kirkland. (2016) Perspective: Targeting the JAK/STAT pathway to fight age-related dysfunction. Pharmacological Research 111, pages 152-154.
Crossref
Crossref
Gary J. Schiller, Pamela Tuttle & Pinkal Desai. (2016) Allogeneic Hematopoietic Stem Cell Transplantation in FLT3 -ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation. Biology of Blood and Marrow Transplantation 22:6, pages 982-990.
Crossref
Crossref
Jennifer M. Fox, James R. Moynihan, Bryan T. Mott, Jennifer R. Mazzone, Nicole M. Anders, Patrick A. Brown, Michelle A. Rudek, Jun O. Liu, Ravit Arav-Boger, Gary H. Posner, Curt I. Civin & Xiaochun Chen. (2016)
Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted
in vivo
, and synergized with antileukemic drugs
. Oncotarget 7:6, pages 7268-7279.
Crossref
Crossref
Bao-hua Hou, Zhi-xiang Jian, Peng Cui, Shao-jie Li, Rui-qing Tian & Jin-rui Ou. (2015) miR‐216a may inhibit pancreatic tumor growth by targeting JAK2. FEBS Letters 589:17, pages 2224-2232.
Crossref
Crossref
Khaled A. Shaaban, Sherif I. Elshahawi, Xiachang Wang, Jamie Horn, Madan K. Kharel, Markos Leggas & Jon S. Thorson. (2015)
Cytotoxic Indolocarbazoles from
Actinomadura melliaura
ATCC 39691
. Journal of Natural Products 78:7, pages 1723-1729.
Crossref
Crossref
Hichem Gallala, Jochen Winter, Nadine Veit, Michael Nowak, Sven Perner, Cornelius Courts, Dominik Kraus, Viktor Janzen & Rainer Probstmeier. (2014) Staurosporine analogs promote distinct patterns of process outgrowth and polyploidy in small cell lung carcinoma cells. Tumor Biology 36:4, pages 2725-2735.
Crossref
Crossref
Sherif I. Elshahawi, Khaled A. Shaaban, Madan K. Kharel & Jon S. Thorson. (2015) A comprehensive review of glycosylated bacterial natural products. Chemical Society Reviews 44:21, pages 7591-7697.
Crossref
Crossref
Holly L. Geyer, Robyn M. Scherber, Amylou C. DueckJean-Jacques KiladjianZhijian XiaoStefanie SlotSonja ZweegmanFederico SackmannAna Kerguelen FuentesDolores Hernández-MaraverKonstanze DöhnerClaire N. HarrisonDeepti RadiaPablo MuxiCarlos BessesFrancisco CervantesPeter L. JohanssonBjorn AndreassonAlessandro RambaldiTiziano BarbuiAlessandro M. VannucchiFrancesco PassamontiJan SamuelssonGunnar Birgegard & Ruben A. Mesa. (2014) Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood 123:24, pages 3803-3810.
Crossref
Crossref
Mariano Provencio, Antonio Sánchez & Margarita Sánchez-Beato. (2014) New drugs and targeted treatments in Hodgkin’s lymphoma. Cancer Treatment Reviews 40:3, pages 457-464.
Crossref
Crossref
Mark S. Butler, Avril A. B. Robertson & Matthew A. Cooper. (2014) Natural product and natural product derived drugs in clinical trials. Nat. Prod. Rep. 31:11, pages 1612-1661.
Crossref
Crossref
Ju Hyeon Seo, Kyung Hee Jung, Mi Kwon Son, Hong Hua Yan, Ye-Lim Ryu, Jinhee Kim, Jung Kyun Lee, Sungwoo Hong & Soon-Sun Hong. (2013) Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer. Cancer Letters 338:2, pages 271-281.
Crossref
Crossref
Sandip B. Bharate, Sanghapal D. Sawant, Parvinder Pal Singh & Ram A. Vishwakarma. (2013) Kinase Inhibitors of Marine Origin. Chemical Reviews 113:8, pages 6761-6815.
Crossref
Crossref
David A. Sweetser & Howard J. Weinstein. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood
355
373
.
Jens Köhler, German Erlenkamp, Adrien Eberlin, Tobias Rumpf, Inna Slynko, Eric Metzger, Roland Schüle, Wolfgang Sippl & Manfred Jung. (2012) Lestaurtinib Inhibits Histone Phosphorylation and Androgen-Dependent Gene Expression in Prostate Cancer Cells. PLoS ONE 7:4, pages e34973.
Crossref
Crossref
Jorrit J. Hornberg. 2012. Designing Multi-Target Drugs. Designing Multi-Target Drugs
1
13
.
T. Prebet, A. Etienne & N. Vey. (2012) Prise en charge thérapeutique des leucémies aiguës myéloïdes. EMC - Hématologie 7:1, pages 1-17.
Crossref
Crossref
N Rajan, R Elliott, O Clewes, A Mackay, J S Reis-Filho, J Burn, J Langtry, M Sieber-Blum, C J Lord & A Ashworth. (2011) Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours. Oncogene 30:41, pages 4243-4260.
Crossref
Crossref
Tania Diaz, Alfons Navarro, Gerardo Ferrer, Bernat Gel, Anna Gaya, Rosa Artells, Beatriz Bellosillo, Mar Garcia-Garcia, Sergi Serrano, Antonio Martínez & Mariano Monzo. (2011) Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis. PLoS ONE 6:4, pages e18856.
Crossref
Crossref